U.S. Markets closed
  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     
  • Dow 30

    31,176.01
    -12.37 (-0.04%)
     
  • Nasdaq

    13,530.92
    +73.67 (+0.55%)
     
  • Russell 2000

    2,141.42
    -19.20 (-0.89%)
     
  • Crude Oil

    53.03
    -0.28 (-0.53%)
     
  • Gold

    1,869.90
    +3.40 (+0.18%)
     
  • Silver

    26.00
    +0.24 (+0.93%)
     
  • EUR/USD

    1.2173
    +0.0058 (+0.4747%)
     
  • 10-Yr Bond

    1.1090
    +0.0190 (+1.74%)
     
  • Vix

    21.32
    -0.26 (-1.20%)
     
  • GBP/USD

    1.3728
    +0.0073 (+0.5313%)
     
  • USD/JPY

    103.5160
    -0.0540 (-0.0521%)
     
  • BTC-USD

    30,441.16
    -4,510.52 (-12.91%)
     
  • CMC Crypto 200

    600.67
    -79.24 (-11.65%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Allena Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 2:30 p.m. ET.

A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com